SCHEMBL4462676

SCHEMBL4462676

CS(=O)(=O)c1cccc(N(c2ccc(C(F)(F)F)nc2)C(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.41
PTGS1 P23219 1/20 0.41
SYK P43405 3/20 0.39
TAAR1 Q96RJ0 1/20 0.38
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
MAP4K4 O95819 1/20 0.37
PIK3CA P42336 1/20 0.37
KCNH2 Q12809 1/20 0.37
MINK1 Q8N4C8 1/20 0.37
PI4KB Q9UBF8 1/20 0.37
GRM2 Q14416 3/20 0.37
SLC40A1 Q9NP59 1/20 0.36
CYP3A4 P08684 3/20 0.36
LRRK2 Q5S007 1/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4458284 0.91 PTGS2 (0.44) PTGS2PTGS1SYKPDE4APDE4B
SCHEMBL4460584 0.88 TAAR1 (0.44) PTGS2TAAR1GRM2LRRK2
SCHEMBL4459549 0.87 TSHR (0.46) PTGS2PTGS1TAAR1KCNH2CYP3A4
SCHEMBL4472842 0.87 TAAR1 (0.40) PTGS2PTGS1TAAR1PDE4APDE4B
SCHEMBL4461909 0.85 TAAR1 (0.39) PTGS2PTGS1TAAR1PDE4APDE4B
SCHEMBL4458283 0.84 KCNA5 (0.44) PTGS2TAAR1KCNH2GRM2CYP3A4
SCHEMBL4472149 0.84 TAAR1 (0.41) PTGS2TAAR1GRM2LRRK2
SCHEMBL4457222 0.84 TAAR1 (0.43) PTGS2TAAR1GRM2LRRK2
SCHEMBL4459544 0.84 RORC (0.47) PTGS2PTGS1PDE4APDE4BPDE4C
SCHEMBL4462469 0.83 OXTR (0.41) PTGS2TAAR1KCNH2LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US claimed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030043-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 PTGS2 3086/4885PTGS1 3089/4885SYK 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.